The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Abstract
This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be 868 million dollars. However, our estimates vary from around 500 million dollars to more than 2,000 million dollars, depending on the therapy or the developing firm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
Henderson, R., & Cockburn, I. (1996) · The RAND Journal of Economics · doi:10.2307/2555791 · Cited by 1,388
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1995) · PharmacoEconomics · doi:10.2165/00019053-199507020-00007 · Cited by 169
Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates
Berndt, E. R., Gottschalk, A. H. B., Philipson, T., & Strobeck, M. W. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1774 · Cited by 106
R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
DiMasi, J. A., Grabowski, H. G., & Vernon, J. (1995) · International Journal of the Economics of Business · doi:10.1080/758519309 · Cited by 73
Cited by
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
Tolerance for Failure and Corporate Innovation
Tian, X., & Wang, T. Y. (2014) · Review of Financial Studies · doi:10.1093/rfs/hhr130 · Cited by 993
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Network Pharmacology Approach for Medicinal Plants: Review and Assessment
Noor, F., Tahir ul Qamar, M., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022) · Pharmaceuticals · doi:10.3390/ph15050572 · Cited by 540
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
The cost of drug development: A systematic review
Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., & Greyson, D. (2011) · Health Policy · doi:10.1016/j.healthpol.2010.12.002 · Cited by 510
Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives
Hahn, M. A., Singh, A. K., Sharma, P., Brown, S. C., & Moudgil, B. M. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4207-5 · Cited by 485
Complement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
Cunningham, C., Ederer, F., & Ma, S. (2021) · Journal of Political Economy · doi:10.1086/712506 · Cited by 452
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Hwang, T. J., Carpenter, D., Lauffenburger, J. C., Wang, B., Franklin, J. M., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6008 · Cited by 442
The FDA Critical Path Initiative and Its Influence on New Drug Development
Woodcock, J., & Woosley, R. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.090506.155819 · Cited by 434
Sung, J. H., & Shuler, M. L. (2009) · Lab on a Chip · doi:10.1039/b901377f · Cited by 431
Key cost drivers of pharmaceutical clinical trials in the United States
Sertkaya, A., Wong, H.-H., Jessup, A., & Beleche, T. (2016) · Clinical Trials · doi:10.1177/1740774515625964 · Cited by 401
Cyanobacteria: an emerging source for drug discovery
Singh, R. K., Tiwari, S. P., Rai, A. K., & Mohapatra, T. M. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.21 · Cited by 370
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351
Economics of New Oncology Drug Development
DiMasi, J. A., & Grabowski, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0803 · Cited by 348
Hanney, S. R., Castle-Clarke, S., Grant, J., Guthrie, S., Henshall, C., Mestre-Ferrandiz, J., Pistollato, M., Pollitt, A., Sussex, J., & Wooding, S. (2015) · Health Research Policy and Systems · doi:10.1186/1478-4505-13-1 · Cited by 348
Do Antitakeover Provisions Spur Corporate Innovation? A Regression Discontinuity Analysis
Chemmanur, T. J., & Tian, X. (2018) · Journal of Financial and Quantitative Analysis · doi:10.1017/s0022109018000029 · Cited by 347
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
The Role of Body-on-a-Chip Devices in Drug and Toxicity Studies
Esch, M. B., King, T. L., & Shuler, M. L. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124629 · Cited by 328
Mitosis is not a key target of microtubule agents in patient tumors
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., & Fojo, T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.228 · Cited by 314
Clinical trial design in the era of precision medicine
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01102-1 · Cited by 305
Predicting drug-disease associations by using similarity constrained matrix factorization
Zhang, W., Yue, X., Lin, W., Wu, W., Liu, R., Huang, F., & Liu, F. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2220-4 · Cited by 303
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
Budish, E., Roin, B. N., & Williams, H. (2015) · American Economic Review · doi:10.1257/aer.20131176 · Cited by 302
Tissue Engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue Models
Caddeo, S., Boffito, M., & Sartori, S. (2017) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00040 · Cited by 285
Cryptosporidium and Giardia in Africa: current and future challenges
Squire, S. A., & Ryan, U. (2017) · Parasites & Vectors · doi:10.1186/s13071-017-2111-y · Cited by 284
Gouglas, D., Thanh Le, T., Henderson, K., Kaloudis, A., Danielsen, T., Hammersland, N. C., Robinson, J. M., Heaton, P. M., & Røttingen, J.-A. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30346-2 · Cited by 280
Spending on new drug development1
Adams, C. P., & Brantner, V. V. (2010) · Health Economics · doi:10.1002/hec.1454 · Cited by 277
Self-citationCryptosporidium in humans and animals—a one health approach to prophylaxis
Ryan, U., Zahedi, A., & Paparini, A. (2016) · Parasite Immunology · doi:10.1111/pim.12350 · Cited by 258
Drug discovery through stem cell-based organoid models
Ranga, A., Gjorevski, N., & Lutolf, M. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.006 · Cited by 195
The first frontier: digital biomarkers for neurodegenerative disorders
Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers · doi:10.1159/000477383 · Cited by 162
Speich, B., von Niederhäusern, B., Schur, N., Hemkens, L. G., Fürst, T., Bhatnagar, N., Alturki, R., Agarwal, A., Kasenda, B., Pauli-Magnus, C., et al. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.12.018 · Cited by 146
Novel Methods and Technologies for 21st-Century Clinical Trials: A Review
Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4524 · Cited by 118
Molecular Theranostics: A Primer for the Imaging Professional
Lee, D. Y., & Li, K. C. P. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.11.6797 · Cited by 95
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Shoda, L. K. M., Woodhead, J. L., Siler, S. Q., Watkins, P. B., & Howell, B. A. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1878 · Cited by 75
Human reconstructed skin xenografts on mice to model skin physiology
Salgado, G., Ng, Y. Z., Koh, L. F., Goh, C. S. M., & Common, J. E. (2017) · Differentiation · doi:10.1016/j.diff.2017.09.004 · Cited by 56
Keung, W., Chan, P. K. W., Backeris, P. C., Lee, E. K., Wong, N., Wong, A. O. T., Wong, G. K. Y., Chan, C. W. Y., Fermini, B., Costa, K. D., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1385 · Cited by 54
Priorities for the Priority Review Voucher
Ridley, D. B. (2017) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.16-0600 · Cited by 15
Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks
Mallikarjun, V., & Swift, J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.020 · Cited by 14
Early ADME/T Predictions: Toy or Tool?
Tetko, I. V., & Oprea, T. I. (2008) · Chemoinformatics Approaches to Virtual Screening · doi:10.1039/9781847558879-00240 · Cited by 5
Metadata
- Authors
- Adams, C. P., & Brantner, V. V.
- Venue
- Health Affairs
- Publisher
- Health Affairs Publishing, LLC
- Published
- 2006-03
- Volume
- 25
- Issue
- 2
- Pages
- 420-428
- ISSN
- 0278-2715 (ISSN-L)
- 1544-5208
- OpenAlex
- W2166209362
- Cited by
- 907
- References
- 5
- FWCI
- 89.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.